Dr. Motzer discusses the future of nccRCC management and emerging data or unmet needs he is following.
Stay up to date on practice-changing data in community practice.
AI Predicts Prostate Cancer Prognosis Fairly Across Races
Mack Roach III, MD, discussed a study on artificial intelligence’s generalizability for prostate cancer across racial groups.
Read More
Transforming Prostate Cancer Care Through Personalized Medicine
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
Listen
FDA Approves Belzutifan in Advanced Pheochromocytoma and Paraganglioma
The FDA approved belzutifan as the first oral therapy for advanced or metastatic pheochromocytoma and paraganglioma in patients 12 years and older.
Dizman’s Global Pursuit to Cancer Research and Understanding
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
FDA Issues Refusal to File for Nogapendekin Alfa Plus BCG in Papillary NMIBC
The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior positive feedback.
Confronting Prostate Cancer Misinformation in the Digital Age
In an interview, Stacy Loeb, MD, discussed a study analyzing prostate cancer misinformation on social media.